| Market Cap | 164.23M | P/E | 12.48 | EPS this Y | -49.60% | Ern Qtrly Grth | -99.80% |
| Income | 15.82M | Forward P/E | 10.24 | EPS next Y | - | 50D Avg Chg | -8.00% |
| Sales | 61.74M | PEG | - | EPS past 5Y | 14.30% | 200D Avg Chg | -17.00% |
| Dividend | N/A | Price/Book | 2.63 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 2.00 | Quick Ratio | 3.28 | Shares Outstanding | 6.99M | 52W Low Chg | 25.00% |
| Insider Own | 22.86% | ROA | 17.07% | Shares Float | 5.50M | Beta | 0.97 |
| Inst Own | 47.07% | ROE | 22.02% | Shares Shorted/Prior | 678.42K/756.97K | Price | 23.97 |
| Gross Margin | 88.67% | Profit Margin | 25.62% | Avg. Volume | 50,885 | Target Price | 40.00 |
| Oper. Margin | 36.99% | Earnings Date | Nov 7 | Volume | 22,957 | Change | -5.48% |
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
| B. Riley Securities | Neutral | Nov 2, 22 |
| B. Riley Securities | Buy | May 3, 22 |
| B. Riley Securities | Buy | Mar 7, 22 |
| B. Riley Securities | Buy | Nov 2, 21 |
| B. Riley Securities | Buy | Oct 26, 21 |
| B. Riley Securities | Buy | May 4, 21 |
| B. Riley Securities | Buy | Jun 23, 20 |
| HC Wainwright & Co. | Jul 29, 15 | |
| Aegis Capital | Buy | Jun 5, 14 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SEMLER ERIC | Director Director | Sep 11 | Buy | 27.6 | 77,771 | 2,146,480 | 77,771 | 09/13/23 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 28 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 03/01/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 28 | Sell | 73.03 | 2,000 | 146,060 | 03/01/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 15 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 02/16/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 15 | Sell | 76.81 | 2,000 | 153,620 | 02/16/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 07 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 02/07/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 07 | Sell | 79.38 | 2,000 | 158,760 | 02/07/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 01 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 02/01/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Feb 01 | Sell | 76.78 | 2,000 | 153,560 | 02/01/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Jan 24 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 01/26/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Jan 24 | Sell | 73.03 | 2,000 | 146,060 | 01/26/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Jan 18 | Option | 2.1 | 2,000 | 4,200 | 2,000 | 01/21/22 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Jan 18 | Sell | 76.83 | 2,000 | 153,660 | 01/21/22 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Oct 25 | Sell | 144.74 | 1,250 | 180,925 | 23,571 | 10/28/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Aug 18 | Sell | 109.69 | 1,250 | 137,112 | 36,071 | 08/18/21 |
| Pan Wayne T | Director Director | Jun 14 | Option | 3.55 | 46,333 | 164,482 | 45,231 | 06/14/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | May 26 | Sell | 108.93 | 2,500 | 272,325 | 51,071 | 05/26/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Apr 20 | Option | 0.52 | 1,250 | 650 | 1,250 | 04/20/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Apr 20 | Sell | 109.84 | 1,250 | 137,300 | 04/20/21 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Apr 13 | Option | 0.52 | 1,250 | 650 | 1,250 | 04/13/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Apr 13 | Sell | 108.21 | 1,250 | 135,262 | 04/13/21 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Mar 30 | Option | 0.52 | 1,250 | 650 | 1,250 | 03/30/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Mar 30 | Sell | 111 | 1,250 | 138,750 | 03/30/21 | |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Jan 21 | Sell | 91.36 | 1,250 | 114,200 | 53,571 | 01/21/21 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Sell | 82.93 | 1,250 | 103,663 | 58,571 | 12/22/20 |
| Murphy-Chutorian Douglas | Chief Executive Offi.. Chief Executive Officer | Dec 15 | Sell | 86.39 | 1,250 | 107,988 | 59,821 | 12/15/20 |